Form 8-K CYTOKINETICS INC For: Oct 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
Cytokinetics (CYTK) Posts Narrower than Expected Q3 Loss
October 31, 2014 9:08 AM EDTCytokinetics (NASDAQ: CYTK) reported Q3 EPS of ($0.16), $0.07 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $9.4 million versus the consensus estimate of $7.43 million.
"In the third quarter, Cytokinetics made considerable progress across our development stage programs as we elaborated in our... More
